Macular Degeneration Association

Therapeutic Areas: Oncology | Hematology

Hematologic Neoplasms Clinical Trials

A listing of Hematologic Neoplasms medical research trials actively recruiting patient volunteers. Click on the closest city to find more detailed information on a research study in your area.

 

Arizona

Scottsdale Arizona 85259-5499

A clinical trial seeking patients for a research study for the treatment of Haematological Malignancy, Multile Pyeolma (SAR650984)

Scottsdale Arizona 85258

A Phase 1 clinical study for patients with Hematologic Neoplasms

Scottsdale Arizona 85259

Patients are needed to participate in a clinical research study evaluating CC-486 (Oral Azacitidine) and Vidaza

Scottsdale Arizona 85258

Patients are needed to participate in a clinical research study evaluating CC-486 (Oral Azacitidine) and Vidaza

California

UPDATED

Duarte California 91010-301

Patients are needed to participate in a clinical research study evaluating AG-221 for the treatment of Relapsed and/or Primary Refractory AML as Defined by WHO Criteria, Untreated AML, ≥60 Years of Age and Not a Candidate for Standard Therapy or Recurrent or Refractory Myelodysplastic Syndrome

UPDATED

Stanford California 94305

Patients are needed to participate in a clinical research study evaluating AG-221 for the treatment of Relapsed and/or Primary Refractory AML as Defined by WHO Criteria, Untreated AML, ≥60 Years of Age and Not a Candidate for Standard Therapy or Recurrent or Refractory Myelodysplastic Syndrome

Los Angeles California 90027

A clinical trial to evaluate treatments using BPX-501 T cells and AP1903 for patients

San Francisco California 94117

A clinical trial seeking patients for a research study for the treatment of Haematological Malignancy, Multile Pyeolma (SAR650984)

San Francisco California 94143

A Phase 1 clinical study for patients with Hematologic Neoplasms

Colorado

UPDATED

Aurora Colorado 80045

Patients are needed to participate in a clinical research study evaluating AG-221 for the treatment of Relapsed and/or Primary Refractory AML as Defined by WHO Criteria, Untreated AML, ≥60 Years of Age and Not a Candidate for Standard Therapy or Recurrent or Refractory Myelodysplastic Syndrome

District of Columbia

Washington District of Columbia 20010

A clinical trial to evaluate treatments using BPX-501 T cells and AP1903 for patients

Florida

UPDATED

Miami Florida 33136

Patients are needed to participate in a clinical research study evaluating AG-221 for the treatment of Relapsed and/or Primary Refractory AML as Defined by WHO Criteria, Untreated AML, ≥60 Years of Age and Not a Candidate for Standard Therapy or Recurrent or Refractory Myelodysplastic Syndrome

UPDATED

Sarasota Florida 34232

Patients are needed to participate in a clinical research study evaluating AG-221 for the treatment of Relapsed and/or Primary Refractory AML as Defined by WHO Criteria, Untreated AML, ≥60 Years of Age and Not a Candidate for Standard Therapy or Recurrent or Refractory Myelodysplastic Syndrome

UPDATED

Tampa Florida 33612

Patients are needed to participate in a clinical research study evaluating AG-221 for the treatment of Relapsed and/or Primary Refractory AML as Defined by WHO Criteria, Untreated AML, ≥60 Years of Age and Not a Candidate for Standard Therapy or Recurrent or Refractory Myelodysplastic Syndrome

Georgia

Atlanta Georgia 30322

A clinical trial to evaluate treatments using BPX-501 T cells and AP1903 for patients

Illinois

UPDATED

Chicago Illinois 60611-3008

Patients are needed to participate in a clinical research study evaluating AG-221 for the treatment of Relapsed and/or Primary Refractory AML as Defined by WHO Criteria, Untreated AML, ≥60 Years of Age and Not a Candidate for Standard Therapy or Recurrent or Refractory Myelodysplastic Syndrome

Maryland

Baltimore Maryland 21231

A clinical trial to evaluate treatments using CC-486 for patients with Hematologic Neoplasm or Neoplasms

Baltimore Maryland 21287

A Phase 1 clinical study for patients with Hematologic Neoplasms

Massachusetts

UPDATED

Boston Massachusetts 02215

Patients are needed to participate in a clinical research study evaluating AG-221 for the treatment of Relapsed and/or Primary Refractory AML as Defined by WHO Criteria, Untreated AML, ≥60 Years of Age and Not a Candidate for Standard Therapy or Recurrent or Refractory Myelodysplastic Syndrome

UPDATED

Boston Massachusetts 02117

Patients are needed to participate in a clinical research study evaluating AG-221 for the treatment of Relapsed and/or Primary Refractory AML as Defined by WHO Criteria, Untreated AML, ≥60 Years of Age and Not a Candidate for Standard Therapy or Recurrent or Refractory Myelodysplastic Syndrome

Boston Massachusetts 02215

A clinical trial to evaluate treatments using BPX-501 T cells and AP1903 for patients

Boston Massachusetts 02215

A Phase 1 clinical study for patients with Hematologic Neoplasms

Michigan

Detroit Michigan 48201

A Phase 1 clinical study for patients with Hematologic Neoplasms

Minnesota

UPDATED

Rochester Minnesota 55905

Patients are needed to participate in a clinical research study evaluating AG-221 for the treatment of Relapsed and/or Primary Refractory AML as Defined by WHO Criteria, Untreated AML, ≥60 Years of Age and Not a Candidate for Standard Therapy or Recurrent or Refractory Myelodysplastic Syndrome

Missouri

UPDATED

St. Louis Missouri 63110

Patients are needed to participate in a clinical research study evaluating AG-221 for the treatment of Relapsed and/or Primary Refractory AML as Defined by WHO Criteria, Untreated AML, ≥60 Years of Age and Not a Candidate for Standard Therapy or Recurrent or Refractory Myelodysplastic Syndrome

St. Louis Missouri 63110

A Phase 1 clinical study for patients with Hematologic Neoplasms

New Jersey

Hackensack New Jersey 07601

A clinical trial seeking patients for a research study for the treatment of Haematological Malignancy, Multile Pyeolma (SAR650984)

New Brunswick New Jersey 08903

Patients are needed to participate in a clinical research study evaluating CC-486 (Oral Azacitidine) and Vidaza

New York

UPDATED

New York New York 10065

Patients are needed to participate in a clinical research study evaluating AG-221 for the treatment of Relapsed and/or Primary Refractory AML as Defined by WHO Criteria, Untreated AML, ≥60 Years of Age and Not a Candidate for Standard Therapy or Recurrent or Refractory Myelodysplastic Syndrome

UPDATED

New York New York 10065

Patients are needed to participate in a clinical research study evaluating AG-221 for the treatment of Relapsed and/or Primary Refractory AML as Defined by WHO Criteria, Untreated AML, ≥60 Years of Age and Not a Candidate for Standard Therapy or Recurrent or Refractory Myelodysplastic Syndrome

Bronx New York 10467

A clinical trial to evaluate treatments using BPX-501 T cells and AP1903 for patients

New York New York

A clinical research study of Ibrutinib and Nivolumab for the treatment of Hematologic Neoplasms, Hematologic Malignancies

New York New York 10021

A Phase 1 clinical study for patients with Hematologic Neoplasms

Ohio

UPDATED

Cleveland Ohio 44195

Patients are needed to participate in a clinical research study evaluating AG-221 for the treatment of Relapsed and/or Primary Refractory AML as Defined by WHO Criteria, Untreated AML, ≥60 Years of Age and Not a Candidate for Standard Therapy or Recurrent or Refractory Myelodysplastic Syndrome

UPDATED

Gahanna Ohio 43230

Patients are needed to participate in a clinical research study evaluating AG-221 for the treatment of Relapsed and/or Primary Refractory AML as Defined by WHO Criteria, Untreated AML, ≥60 Years of Age and Not a Candidate for Standard Therapy or Recurrent or Refractory Myelodysplastic Syndrome

Oregon

UPDATED

Portland Oregon 97201-3098

Patients are needed to participate in a clinical research study evaluating AG-221 for the treatment of Relapsed and/or Primary Refractory AML as Defined by WHO Criteria, Untreated AML, ≥60 Years of Age and Not a Candidate for Standard Therapy or Recurrent or Refractory Myelodysplastic Syndrome

Portland Oregon 97239

A Phase 1 clinical study for patients with Hematologic Neoplasms

South Carolina

Greenville South Carolina 29605

Patients are needed to participate in a clinical research study evaluating CC-486 (Oral Azacitidine) and Vidaza

Tennessee

UPDATED

Nashville Tennessee 37203

Patients are needed to participate in a clinical research study evaluating AG-221 for the treatment of Relapsed and/or Primary Refractory AML as Defined by WHO Criteria, Untreated AML, ≥60 Years of Age and Not a Candidate for Standard Therapy or Recurrent or Refractory Myelodysplastic Syndrome

Nashville Tennessee 37232

A clinical trial seeking patients for a research study for the treatment of Haematological Malignancy, Multile Pyeolma (SAR650984)

Nashville Tennessee 37232-6307

Patients are needed to participate in a clinical research study evaluating CC-486 (Oral Azacitidine) and Vidaza

Texas

UPDATED

Dallas Texas 75390-85520

Patients are needed to participate in a clinical research study evaluating AG-221 for the treatment of Relapsed and/or Primary Refractory AML as Defined by WHO Criteria, Untreated AML, ≥60 Years of Age and Not a Candidate for Standard Therapy or Recurrent or Refractory Myelodysplastic Syndrome

UPDATED

Houston Texas 77030

Patients are needed to participate in a clinical research study evaluating AG-221 for the treatment of Relapsed and/or Primary Refractory AML as Defined by WHO Criteria, Untreated AML, ≥60 Years of Age and Not a Candidate for Standard Therapy or Recurrent or Refractory Myelodysplastic Syndrome

Dallas Texas 75390

A clinical trial to evaluate treatments using BPX-501 T cells and AP1903 for patients

Houston Texas 77030

A clinical trial to evaluate treatments using BPX-501 T cells and AP1903 for patients

Houston Texas 77030

A clinical trial to evaluate treatments using CC-486 for patients with Hematologic Neoplasm or Neoplasms

Houston Texas 77030

A Phase 1 clinical study for patients with Hematologic Neoplasms

Houston Texas 77030

Patients are needed to participate in a clinical research study evaluating CC-486 (Oral Azacitidine) and Vidaza

San Antonio Texas 78229

A Phase 1 clinical study for patients with Hematologic Neoplasms

Utah

Salt Lake City Utah 84112-5550

A clinical trial seeking patients for a research study for the treatment of Haematological Malignancy, Multile Pyeolma (SAR650984)